Business Context and Reporting Period
SciSparc Ltd. filed a Form 6-K report for the month of February 2026, dated February 2, 2026. The filing serves to disclose a corporate development regarding its subsidiary, NeuroThera Labs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event rather than a financial statement.
Material Changes
The primary material change disclosed is the granting of a U.S. patent to NeuroThera Labs for cannabinoid technology designed to overcome antimicrobial resistance, specifically targeting MRSA (Methicillin-resistant Staphylococcus aureus).
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies within the body of the Form 6-K text provided.
Investor Verification Points
- Verify the specific scope and claims of the U.S. patent granted to NeuroThera Labs.
- Review the full text of the press release (Exhibit 99.1) for details on the commercialization timeline of the new technology.
- Confirm the regulatory status of the cannabinoid technology in the U.S. market.